Details

Autor(en) / Beteiligte

• Cooreman, Axelle
• Caufriez, Anne
• Tabernilla, Andrés
• Van Campenhout, Raf
• Leroy, Kaat
• Kadam, Prashant
• Sanz Serrano, Julen
• Dos Santos Rodrigues, Bruna
• Annaert, Pieter
• Vinken, Mathieu

Titel

Effects of Drugs Formerly Proposed for COVID-19 Treatment on Connexin43 Hemichannels

Ist Teil von

• International journal of molecular sciences, 2022-04, Vol.23 (9), p.5018

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Connexin43 (Cx43) hemichannels form a pathway for cellular communication between the cell and its extracellular environment. Under pathological conditions, Cx43 hemichannels release adenosine triphosphate (ATP), which triggers inflammation. Over the past two years, azithromycin, chloroquine, dexamethasone, favipiravir, hydroxychloroquine, lopinavir, remdesivir, ribavirin, and ritonavir have been proposed as drugs for the treatment of the coronavirus disease 2019 (COVID-19), which is associated with prominent systemic inflammation. The current study aimed to investigate if Cx43 hemichannels, being key players in inflammation, could be affected by these drugs which were formerly designated as COVID-19 drugs. For this purpose, Cx43-transduced cells were exposed to these drugs. The effects on Cx43 hemichannel activity were assessed by measuring extracellular ATP release, while the effects at the transcriptional and translational levels were monitored by means of real-time quantitative reverse transcriptase polymerase chain reaction analysis and immunoblot analysis, respectively. Exposure to lopinavir and ritonavir combined (4:1 ratio), as well as to remdesivir, reduced Cx43 mRNA levels. None of the tested drugs affected Cx43 protein expression.